André, Ana S.
Dias, Joana N. R.
Aguiar, Sandra
Nogueira, Sara
Bule, Pedro
Carvalho, Joana Inês
António, João P. M.
Cavaco, Marco
Neves, Vera
Oliveira, Soraia
Vicente, Gonçalo
Carrapiço, Belmira
Braz, Berta São
Rütgen, Barbara
Gano, Lurdes
Correia, João D. G.
Castanho, Miguel
Goncalves, Joao
Gois, Pedro M. P.
Gil, Solange
Tavares, Luís
Aires-da-Silva, Frederico
Funding for this research was provided by:
Fundação para a Ciência e Tecnologia (SFRH/BD/131468/2017, LA/P/0059/2020-AL4AnimalS, SAICT/2017/32085, SAICT/2017/32085, LA/P/0059/2020-AL4AnimalS, UIDB/04138/2020, UIDB/04138/2020, SAICT/2017/32085, SAICT/2017/32085, SAICT/2017/32085, SAICT/2017/32085, SAICT/2017/32085, LA/P/0059/2020-AL4AnimalS, SAICT/2017/32085, SAICT/2017/32085, SAICT/2017/32085, UIDB/04138/2020, SAICT/2017/32085, SAICT/2017/32085, SAICT/2017/32085, SAICT/2017/32085)
Article History
Received: 13 December 2022
Accepted: 14 March 2023
First Online: 24 March 2023
Competing interests
: The authors would like to disclose that: FAS, ASA, JD, SIA, SO, LT, JIC, JA and PG have pending patent applications related to the development of ADCs from rabbit derived single-domain antibodies (PCT/IB2022/056303) and ROS-linker sensitive diazaborines (Application number: 20211000023853). All other authors have no competing/conflict of interest.